Publicaciones en las que colabora con OLGA MAIZ ALONSO (36)

2024

  1. Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis

    European Journal of Internal Medicine, Vol. 129, pp. 78-86

  2. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature

    Arthritis Research and Therapy, Vol. 26, Núm. 1

  3. Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients

    Seminars in Arthritis and Rheumatism, Vol. 68

2023

  1. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients

    Seminars in Arthritis and Rheumatism, Vol. 58

  2. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 829-836

2022

  1. Biologic therapy in refractory neurobehçet's disease: a multicentre study of 41 patients and literature review

    Rheumatology (Oxford, England), Vol. 61, Núm. 11, pp. 4427-4436

  2. Heart Transplantation in Systemic Sclerosis: A Therapeutic Option. Presentation of a Case and Literature Review

    Reumatologia Clinica, Vol. 18, Núm. 6, pp. 374-376

  3. Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients

    Clinical and Experimental Rheumatology

  4. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients

    RMD Open, Vol. 8, Núm. 2

  5. Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients

    Therapeutic Advances in Musculoskeletal Disease, Vol. 14

2021

  1. Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients

    Rheumatology (Oxford, England), Vol. 61, Núm. 1, pp. 299-308

  2. Long-term Follow-up and optimization of infliximab in refractory uveitis due to Behçet Disease: National study of 103 white patients

    Journal of Rheumatology, Vol. 48, Núm. 5, pp. 741-750

2020

  1. Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients

    Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 4, pp. 608-615

2019

  1. Gut microbiome and serum metabolome analyses identify molecular biomarkers and altered glutamate metabolism in fibromyalgia

    EBioMedicine, Vol. 46, pp. 499-511

2018

  1. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease

    Ophthalmology, Vol. 125, Núm. 9, pp. 1444-1451

2017

  1. Anti–Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis–Associated Uveitis Refractory to Anti–Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients

    Arthritis and Rheumatology, Vol. 69, Núm. 3, pp. 668-675

  2. Bilateral peripheral ulcerative keratitis in patient with rheumatoid arthritis: Treatment with infliximab

    Revista Mexicana de Oftalmologia, Vol. 91, Núm. 1, pp. 51-54

  3. Categorización diagnóstica según los criterios del First International Workshop on Ocular Sarcoidosis (FIWOS) en una serie de 11 pacientes

    Reumatologia Clinica

  4. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project

    Journal of Clinical Lipidology, Vol. 11, Núm. 3, pp. 749-756.e3

2016

  1. Certolizumab Pegol, a New Anti-TNF-α in the Armamentarium against Ocular Inflammation

    Ocular Immunology and Inflammation, Vol. 24, Núm. 2, pp. 167-172